The safety and efficacy of dabrafenib plus trametinib for patients with brain metastatic melanoma: a systematic review and meta-analysis

Abstract Background Brain metastases (BM) are common complications of metastatic cancer and typically occur in patients with melanoma. This study aims to investigate the dabrafenib plus trametinib for patients diagnosed with melanoma brain metastasis (MBM). Method This review adhered to the Preferre...

Full description

Bibliographic Details

Published in:	Discover Oncology
Main Authors:	Mohammad Amin Habibi, Mohammad Sina Mirjani, Bardia Hajikarimloo, Mohsen Dashti, Afsaneh Ghasemzadeh, Seyed Hesam Hojjat, Mohammad Shahir Eftekhar, Kosar Doraghi, Yalda Ghazizadeh, Fateme Aghaei, Shaghayegh Karami, Mehrshad Edalat, Farhang Rashidi, Sajjad Ahmadpour, Sina Ahmadi
Format:	Article
Language:	English
Published:	Springer 2025-06-01
Subjects:	BRAF inhibitor Dabrafenib MEK inhibitor Melanoma Melanoma brain metastasis Trametinib
Online Access:	https://doi.org/10.1007/s12672-025-02778-8